Get started
Work

A phase Ib/II trial of first-line trastuzumab, nivolumab, gemcitabine, and cisplatin in HER2-positive biliary tract cancer (HERBOT): A multi-institutional study from the Korean Cancer Study Group.

Year: 2026
Type: conference-abstract
DOI: 10.1200/jco.2026.44.16_suppl.4016
Authors: Choong-kun Lee, Taek Chung, Il Hwan Kim, Hong Jae Chon, Jin Won Kim, Se Jun Park, Bae Woo Kyun, Jung Hun Kang, Changhoon Yoo, Dong-Hoe Koo, Sora Kang, Jung Yong Hong, Ju Won Kim, Ji-Hyang Lee, Chang Ho Ahn, Chang Gon Kim, Hye Jin Choi
Institutions: Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Inje University, Inje University Haeundae Paik Hospital, CHA University Bundang Medical Center, CHA University, Seoul National University, Seoul National University Bundang Hospital, Korea University Anam Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Chonnam National University Hwasun Hospital, Gyeongsang National University, Asan Medical Center, University of Ulsan, Kangbuk Samsung Hospital, Sungkyunkwan University, Chungnam National University, Chungnam National University Hospital, Samsung Medical Center, Lunit (South Korea)
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: closed
OpenAlex ID: W7162551637
Cites:
Cited by:
Related to: